BI-1206

First patient enrolled in Phase 2a study arm combining BI-1206 with rituximab and acalabrutinibwith initial data expected YE 2024 Clinical supply agreement for acalabrutinib with AstraZeneca in place Lund, Sweden – September 12, 2024 – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has enrolled the first patient in the triple combination arm of the Phase 1/2a study of its anti-FcgRIIB antibody, BI-1206 in non-Hodgkin's lymphoma (NHL). The Phase 2a study arm will combine the subcutaneous formulation of BI-1206 and rituximab with Calquence® (acalabrutinib), a selective inhibitor of Bruton's tyrosine kinase (BTK). Approximately 30 patients are expected to be enrolled in Spain, Germany, the US, and Brazil. Preliminary data are expected by the end of 2024. In February 2024 BioInvent signed a clinical supply agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to provide Calquence® for the combination arm. "The enrolment of the first patient in the study is an important milestone as we move forward to evaluate this triple combination as a potential new treatment option for patients with non-Hodgkin's lymphoma," said Martin Welschof, Chief Executive Officer of BioInvent. "The combination of BI-1206 and rituximab has already demonstrated promising signs of clinical efficacy with a favorable safety profile, and we have strong reasons to believe that the addition of acalabrutinib will increase response rates even further; the subcutaneous formulation of BI-1206 is expected to provide a great deal of flexibility and further improve the tolerability of the treatment." About BI-1206BI-1206 is one of BioInvent’s most advanced drug candidates and is developed to re-establish the clinical effect of existing cancer treatments such as pembrolizumab and rituximab, drugs with combined global sales of approximately USD 28.5 billion annually. The drug candidate is evaluated in two separate clinical programs, one for the treatment of non-Hodgkin’s lymphoma (NHL, a type of blood cancer) and one for the treatment of solid tumors. Two delivery formulations (intravenous (IV) and subcutaneous (SC)) of BI-1206 are being evaluated in parallel. BI-1206 in NHLAll patients in the ongoing Phase 1/2a study (NCT03571568) have previously been treated with one or more rituximab containing treatments. Latest results were presented in connection with EHA (European Hematology Association) congress in June 2024: the intravenous (IV) Phase 1 part (dose escalation) showcased responses across the dose range of 30-100 mg, including 5 patients with complete response (CR), 1 with partial response (PR) and 6 patients with stable disease (SD) out of 17 evaluable patients. First data from the subcutaneous (SC) Phase 1 part (dose escalation) showed 1 CR, 2 PR and 1 SD out of 4 evaluable patients. About BioInventBioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow us on the social media platform X: @BioInvent. For further information, please contact:Cecilia Hofvander, Senior Director Investor RelationsPhone: +46 (0)46 286 85 50Email: cecilia.hofvander@bioinvent.comBioInvent International AB (publ)Co. Reg. No. Org nr: 556537-7263Visiting address: Ideongatan 1Mailing address: 223 70 LUNDPhone: +46 (0)46 286 85 50www.bioinvent.com The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

2024年6月26日，CASI制药(“CASI”或“公司”)宣布，公司计划在2024年底前向美国食品药品监督管理局（“FDA”）提交CID-103的临床试验申请（“IND”），用于治疗肾移植患者的抗体介导排斥反应（“AMR”）。CID-103是一种全人源IgG1抗CD38单克隆抗体，可识别CD38靶点上的独特表位。临床前数据显示，与其他抗CD38 单抗相比，CID-103显示出更好的疗效和安全性。公司相信，通过之前宣布的私募融资所得以及现有的现金及现金等价物，公司将有足够的资金完成AMR的二期临床试验。 此外，CASI还宣布，公司董事会已于2024年6月21日收到董事长兼首席执行官何为无博士发出的初步非约束性要约（“要约”），要求以总价4000万美元收购公司在中国的所有业务及所有管线产品（包括但不限于迈维宁®、富洛特®、CNCT19、BI-1206、CB-5339、CID-103和塞替派）在亚洲（日本除外）的引进许可、分销及相关权利，其中包括承担公司高达2000万美元的债务（“拟议交易”）。 董事会于2024年6月25日成立了一个仅由现任独立董事组成的特别委员会（“特别委员会”），以评估要约中的拟议交易及公司在中国业务运营方面的其他战略和商业选择。 董事会及特别委员会提醒公司股东及考虑买卖公司证券的人士，公司尚未就拟议交易或可能采取的其他战略选择做出任何决定。公司不能保证会收到任何最终要约，也无法保证会达成与拟议交易有关的任何最终协议，亦无法确保批准或完成任何其他交易。除适用法律要求外，公司不承担更新本交易或任何其他交易相关信息的义务。